Teva Pharmaceutical Industries Ltd (TEVA) 63.01 $TEVA
Will Teva Manage To Complete The Takeover Of Mylan?
Emerging Equities - at Seeking Alpha - 2 hrs 59 mins ago
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), ASPX: 100.79 (+0.09)
Fitch Places Teva Pharmaceutical's Ratings on Watch Negative on Proposed Mylan Acquisition
Business Wire - Wed Apr 22, 4:36PM CDT
Fitch Ratings has placed the ratings of Teva Pharmaceutical Industries Limited (NYSE: TEVA) and its subsidiaries, including the 'BBB+' long-term Issuer Default Rating, on Rating Watch Negative.
TEVA: 63.01 (-1.15)
Don't Cash In On Perrigo Yet, Upside Still Possible
Value Hawk - Seeking Alpha - Wed Apr 22, 4:27PM CDT
Summary: We recommend a sell for Perrigo Company (NYSE: PRGO ) with two triggers based on the possible scenarios. First, if Perrigo's price falls to $185, we recommend selling to protect significant gains from recent M&A conversations. On the...
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Teva Proposes to Buy Mylan, Sends Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:11PM CDT
Teva (TEVA) made an offer to acquire Mylan (MYL) for $82 per share in a deal that would create a powerhouse of generics with revenues of more than $30 billion.
ACT: 295.22 (+0.69), PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Concerns About Soaring Generic Prices Could Present Teva With Ultimate Challenge
EP Vantage - Seeking Alpha - Wed Apr 22, 11:31AM CDT
That Teva (NYSE: TEVA ) would declare its interest in Mylan (NASDAQ: MYL ) was a foregone conclusion. The consummation of any such deal is far from certain. An agreement on price would probably get investors in both camps on board, but these are...
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Stock Market News for April 22, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:10AM CDT
Benchmarks finished Tuesday’s trading session mostly lower following a mixed bag of earnings reports
VRTX: 132.85 (+0.65), UTX: 116.96 (+0.01), KMB: 111.85 (-1.30), MYL: 72.40 (-1.67), AMGN: 169.10 (+0.64), XOM: 87.46 (+0.58), SLB: 92.16 (+0.87), RIG: 16.85 (-0.18), IBM: 165.36 (+1.10), EOG: 97.70 (+1.11), DD: 71.44 (+0.75), TEVA: 63.01 (-1.15), CVX: 109.50 (-0.23), REGN: 472.63 (+9.41), TRV: 102.02 (+0.14)
Mylan preparing new bid for Perrigo
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:47AM CDT
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Teva Won't Let Regulators, Poison Pill Stop Its Quest for Mylan
at The Street - Wed Apr 22, 8:46AM CDT
Teva has a path to complete the deal.
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Perrigo Beats on Q3 Earnings, Gives View, Rejects Mylan Bid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:00AM CDT
Perrigo Company's third-quarter fiscal 2015 earnings of $1.85 per share beat the Zacks Consensus Estimate of $1.80.
BIIB: 423.57 (+1.46), PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Key Trends in the Pharmaceutical and Nutritional Supplement Industries Outperforming Other Industries as Increase in Pharma Grade Products & Supplements Grow Globally
PR Newswire - Wed Apr 22, 7:35AM CDT
The Worldwide nutritional supplement market, segmented into groups such as vitamins, pharma grade supplements, protein supplements, probiotics, fish oils, blended supplements, is driven by factors such as increasing global health consciousness and growing consumer income. Some analyst forecasts that the global dietary supplements market was valued at $60 Billion in 2014 and is expected to reach $80 Billion by 2020. Nutrition & Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Vitamin Shoppe (NYSE:VSI), Herbalife Ltd. (NYSE: HLF) and Enzon Pharmaceuticals (NASDAQ: ENZN)
ENZN: 1.70 (+0.20), HLF: 46.63 (-0.13), VSI: 44.50 (+5.54), GNC: 47.56 (+1.60), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Teva Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Mylan
Business Wire - Wed Apr 22, 7:30AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) today announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its proposed acquisition of Mylan N.V. (NASDAQ: MYL). As announced on April 21, 2015, Teva proposed to acquire Mylan for $82.00 per Mylan share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock. Teva's proposal for Mylan implies a total equity value of approximately $43 billion and an enterprise value of approximately $50 billion.
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Downgrade Alert for Teva Pharmaceutical Industries (TEVA)
Comtex SmarTrend(R) - Wed Apr 22, 7:13AM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) was downgraded from Outperform to Market Perform at BMO Capital today. The stock closed yesterday at $64.16 on volume of 24.0 million shares, above average daily volume of 6.1 million. There is potential upside of 1.8% for shares of Teva Pharmaceutical Industries based on a current price of $64.16 and an average consensus analyst price target of $65.30. The stock should discover initial support at its 50-day moving average (MA) of $60.28 and subsequent support at its 200-day MA of $56.20.
TEVA: 63.01 (-1.15)
Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company
PR Newswire - Wed Apr 22, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MRK: 57.69 (+0.03), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), BMY: 66.60 (-0.21)
Wall Street Breakfast: China Shares Extend Bull Run
Wall Street Breakfast - at Seeking Alpha - Wed Apr 22, 5:30AM CDT
PRGO: 201.50 (+8.68), BX: 41.76 (+0.04), SNE: 32.35 (+1.47), GOOG: 539.36 (+5.39), NOV: 53.93 (+0.80), YHOO: 43.97 (-0.52), SPY: 210.63 (+1.03), RIG: 16.85 (-0.18), S: 5.08 (+0.10), CMG: 641.23 (-51.29), FOXA: 34.04 (+0.09), GOOGL: 549.18 (+6.26), TMUS: 34.09 (+0.74), TWC: 149.64 (-2.36), MYL: 72.40 (-1.67), DIS: 107.94 (+0.26), PXD: 172.93 (-0.64), QQQ: 108.65 (+0.59), ARMH: 54.07 (+0.47), TEVA: 63.01 (-1.15), VZ: 49.57 (+0.40), CMCSA: 58.76 (-0.08), EPD: 33.35 (-0.29)
Reuters: Top Mylan shareholders seek deal with Teva
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 2:01AM CDT
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Update - Perrigo's Rejection Of Offer Gives Mylan 5 Strategy Options
Jordan Flannery - at Seeking Alpha - Tue Apr 21, 11:01PM CDT
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Perrigo rejects $29B offer from generic drugmaker Mylan
AP - Tue Apr 21, 5:34PM CDT
NEW YORK (AP) — Over-the-counter medicines maker Perrigo said Tuesday it is turning down a buyout offer from generic drugmaker Mylan that valued the company at $205 per share, or almost $29 billion, because it's too low.
1 Comment
TEVA: 63.01 (-1.15)
Business Highlights
By The Associated Press - AP - Tue Apr 21, 4:54PM CDT
___
TEVA: 63.01 (-1.15)
Perrigo takes 3Q loss, says it won't take Mylan's $29B bid
AP - Tue Apr 21, 4:26PM CDT
DUBLIN (AP) — Irish drug and over-the-counter ingredients maker Perrigo Co. said Tuesday it took a loss in its fiscal third quarter as it prepared to buy a Belgian competitor.
TEVA: 63.01 (-1.15)
Teva offers to buy Mylan in $40.1B cash-and-stock deal
By LINDA A. JOHNSON - AP - Tue Apr 21, 4:30PM CDT
TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
AGN: 240.22 (+2.88), ACT: 295.22 (+0.69), ASPX: 100.79 (+0.09), TEVA: 63.01 (-1.15)
Will Teva Manage To Complete The Takeover Of Mylan?
Emerging Equities - at Seeking Alpha - 2 hrs 59 mins ago
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), ASPX: 100.79 (+0.09)
Fitch Places Teva Pharmaceutical's Ratings on Watch Negative on Proposed Mylan Acquisition
Business Wire - Wed Apr 22, 4:36PM CDT
Fitch Ratings has placed the ratings of Teva Pharmaceutical Industries Limited (NYSE: TEVA) and its subsidiaries, including the 'BBB+' long-term Issuer Default Rating, on Rating Watch Negative.
TEVA: 63.01 (-1.15)
Don't Cash In On Perrigo Yet, Upside Still Possible
Value Hawk - Seeking Alpha - Wed Apr 22, 4:27PM CDT
Summary: We recommend a sell for Perrigo Company (NYSE: PRGO ) with two triggers based on the possible scenarios. First, if Perrigo's price falls to $185, we recommend selling to protect significant gains from recent M&A conversations. On the...
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Teva Proposes to Buy Mylan, Sends Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:11PM CDT
Teva (TEVA) made an offer to acquire Mylan (MYL) for $82 per share in a deal that would create a powerhouse of generics with revenues of more than $30 billion.
ACT: 295.22 (+0.69), PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Concerns About Soaring Generic Prices Could Present Teva With Ultimate Challenge
EP Vantage - Seeking Alpha - Wed Apr 22, 11:31AM CDT
That Teva (NYSE: TEVA ) would declare its interest in Mylan (NASDAQ: MYL ) was a foregone conclusion. The consummation of any such deal is far from certain. An agreement on price would probably get investors in both camps on board, but these are...
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Stock Market News for April 22, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:10AM CDT
Benchmarks finished Tuesday’s trading session mostly lower following a mixed bag of earnings reports
VRTX: 132.85 (+0.65), UTX: 116.96 (+0.01), KMB: 111.85 (-1.30), MYL: 72.40 (-1.67), AMGN: 169.10 (+0.64), XOM: 87.46 (+0.58), SLB: 92.16 (+0.87), RIG: 16.85 (-0.18), IBM: 165.36 (+1.10), EOG: 97.70 (+1.11), DD: 71.44 (+0.75), TEVA: 63.01 (-1.15), CVX: 109.50 (-0.23), REGN: 472.63 (+9.41), TRV: 102.02 (+0.14)
Mylan preparing new bid for Perrigo
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:47AM CDT
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Teva Won't Let Regulators, Poison Pill Stop Its Quest for Mylan
at The Street - Wed Apr 22, 8:46AM CDT
Teva has a path to complete the deal.
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Perrigo Beats on Q3 Earnings, Gives View, Rejects Mylan Bid - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:00AM CDT
Perrigo Company's third-quarter fiscal 2015 earnings of $1.85 per share beat the Zacks Consensus Estimate of $1.80.
BIIB: 423.57 (+1.46), PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Key Trends in the Pharmaceutical and Nutritional Supplement Industries Outperforming Other Industries as Increase in Pharma Grade Products & Supplements Grow Globally
PR Newswire - Wed Apr 22, 7:35AM CDT
The Worldwide nutritional supplement market, segmented into groups such as vitamins, pharma grade supplements, protein supplements, probiotics, fish oils, blended supplements, is driven by factors such as increasing global health consciousness and growing consumer income. Some analyst forecasts that the global dietary supplements market was valued at $60 Billion in 2014 and is expected to reach $80 Billion by 2020. Nutrition & Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Vitamin Shoppe (NYSE:VSI), Herbalife Ltd. (NYSE: HLF) and Enzon Pharmaceuticals (NASDAQ: ENZN)
ENZN: 1.70 (+0.20), HLF: 46.63 (-0.13), VSI: 44.50 (+5.54), GNC: 47.56 (+1.60), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Teva Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Mylan
Business Wire - Wed Apr 22, 7:30AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) today announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its proposed acquisition of Mylan N.V. (NASDAQ: MYL). As announced on April 21, 2015, Teva proposed to acquire Mylan for $82.00 per Mylan share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock. Teva's proposal for Mylan implies a total equity value of approximately $43 billion and an enterprise value of approximately $50 billion.
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Downgrade Alert for Teva Pharmaceutical Industries (TEVA)
Comtex SmarTrend(R) - Wed Apr 22, 7:13AM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) was downgraded from Outperform to Market Perform at BMO Capital today. The stock closed yesterday at $64.16 on volume of 24.0 million shares, above average daily volume of 6.1 million. There is potential upside of 1.8% for shares of Teva Pharmaceutical Industries based on a current price of $64.16 and an average consensus analyst price target of $65.30. The stock should discover initial support at its 50-day moving average (MA) of $60.28 and subsequent support at its 200-day MA of $56.20.
TEVA: 63.01 (-1.15)
Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company
PR Newswire - Wed Apr 22, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MRK: 57.69 (+0.03), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15), BMY: 66.60 (-0.21)
Wall Street Breakfast: China Shares Extend Bull Run
Wall Street Breakfast - at Seeking Alpha - Wed Apr 22, 5:30AM CDT
PRGO: 201.50 (+8.68), BX: 41.76 (+0.04), SNE: 32.35 (+1.47), GOOG: 539.36 (+5.39), NOV: 53.93 (+0.80), YHOO: 43.97 (-0.52), SPY: 210.63 (+1.03), RIG: 16.85 (-0.18), S: 5.08 (+0.10), CMG: 641.23 (-51.29), FOXA: 34.04 (+0.09), GOOGL: 549.18 (+6.26), TMUS: 34.09 (+0.74), TWC: 149.64 (-2.36), MYL: 72.40 (-1.67), DIS: 107.94 (+0.26), PXD: 172.93 (-0.64), QQQ: 108.65 (+0.59), ARMH: 54.07 (+0.47), TEVA: 63.01 (-1.15), VZ: 49.57 (+0.40), CMCSA: 58.76 (-0.08), EPD: 33.35 (-0.29)
Reuters: Top Mylan shareholders seek deal with Teva
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 2:01AM CDT
MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Update - Perrigo's Rejection Of Offer Gives Mylan 5 Strategy Options
Jordan Flannery - at Seeking Alpha - Tue Apr 21, 11:01PM CDT
PRGO: 201.50 (+8.68), MYL: 72.40 (-1.67), TEVA: 63.01 (-1.15)
Perrigo rejects $29B offer from generic drugmaker Mylan
AP - Tue Apr 21, 5:34PM CDT
NEW YORK (AP) — Over-the-counter medicines maker Perrigo said Tuesday it is turning down a buyout offer from generic drugmaker Mylan that valued the company at $205 per share, or almost $29 billion, because it's too low.
1 Comment
TEVA: 63.01 (-1.15)
Business Highlights
By The Associated Press - AP - Tue Apr 21, 4:54PM CDT
___
TEVA: 63.01 (-1.15)
Perrigo takes 3Q loss, says it won't take Mylan's $29B bid
AP - Tue Apr 21, 4:26PM CDT
DUBLIN (AP) — Irish drug and over-the-counter ingredients maker Perrigo Co. said Tuesday it took a loss in its fiscal third quarter as it prepared to buy a Belgian competitor.
TEVA: 63.01 (-1.15)
Teva offers to buy Mylan in $40.1B cash-and-stock deal
By LINDA A. JOHNSON - AP - Tue Apr 21, 4:30PM CDT
TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan for about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators.
AGN: 240.22 (+2.88), ACT: 295.22 (+0.69), ASPX: 100.79 (+0.09), TEVA: 63.01 (-1.15)
